Increased expression of HMGB1 and its receptor RAGE (receptor for advanced glycation end-products) has been observed in many types of tumors, including hepatomas and prostate cancer, and coexpression of HMGB1 and RAGE correlates with tumor invasiveness and poor clinical outcome [14], [15]. This evidence concerns the gene HMGB1 and prostate cancer.